



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03028846.8

EP/04/53544

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 03028846.8
Demande no:

Anmeldetag:
Date of filing: 16.12.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

ALTANA Pharma AG
Byk-Gulden-Strasse 2
78467 Konstanz
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Tricyclic benzimidazoles

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D471/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

1238EPORD01 2003-12 04

- 1 -

Tricyclic Benzimidazoles**Technical field**


The invention relates to novel compounds, which are used in the pharmaceutical industry as active compounds for the production of medicaments.

Prior art

In the international patent application WO 97/47603 (which corresponds to the US Patent 6,465,505), benzimidazole derivatives having a very specific substitution pattern are disclosed, which are said to be suitable for inhibition of gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Summary of the invention

The invention relates to compounds of the formula 1



in which

- R1** is hydrogen, halogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R2** is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R3** is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R4** is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl
- R5** is hydrogen, halogen, 1-4C-alkyl or fluoro-1-4C-alkyl
- R6** is hydrogen, halogen, 1-4C-alkyl or fluoro-1-4C-alkyl
- and the salts of these compounds.

Halogen within the meaning of the invention is bromo, chloro and fluoro.

1238EPORD01 2003-12 04

- 2 -

1-4C-Alkyl represents a straight-chain or branched alkyl group having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and the methyl group.

3-7C-Cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.

3-7C-Cycloalkyl-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one of the aforementioned 3-7C-cycloalkyl groups. Examples which may be mentioned are the cyclopropylmethyl, the cyclohexylmethyl and the cyclohexylethyl group.

1-4C-Alkoxy represents a group, which in addition to the oxygen atom contains one of the aforementioned 1-4C-alkyl groups. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy group.

1-4C-Alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one of the aforementioned 1-4C-alkoxy groups. Examples which may be mentioned are the methoxymethyl, the methoxyethyl group and the butoxyethyl group.

1-4C-Alkoxy-carbonyl (1-4C-alkoxy-CO-) represents a carbonyl group, to which one of the aforementioned 1-4C-alkoxy groups is bonded. Examples which may be mentioned are the methoxycarbonyl ($\text{CH}_3\text{O}-\text{C}(\text{O})-$) and the ethoxycarbonyl group ($\text{CH}_3\text{CH}_2\text{O}-\text{C}(\text{O})-$).

2-4C-Alkenyl represents a straight-chain or branched alkenyl group having 2 to 4 carbon atoms. Examples which may be mentioned are the 2-butenyl, 3-butenyl, 1-propenyl and the 2-propenyl group (allyl group).

2-4C-Alkynyl represents a straight-chain or branched alkynyl group having 2 to 4 carbon atoms. Examples which may be mentioned are the 2-butyne, 3-butyne, and preferably the 2-propyne, group (propargyl group).

Fluoro-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by one or more fluorine atoms. An example which may be mentioned is the trifluoromethyl group.

Fluoro-1-4C-alkoxy represents one of the aforementioned 1-4C-alkoxy groups, which is completely or mainly substituted by fluorine, "mainly" meaning in this connection that more than half of the hydrogen atoms are replaced by fluorine atoms. Examples of completely or mainly fluoro-substituted 1-4C-alkoxy groups which may be mentioned are the 1,1,1,3,3,3-hexafluoro-2-propoxy, the 2-trifluoromethyl-2-propoxy, the 1,1,1-trifluoro-2-propoxy, the perfluoro-tert-butoxy, the 2,2,3,3,4,4,4-heptafluoro-1-butoxy, the 4,4,4-trifluoro-1-butoxy, the 2,2,3,3,3-pentafluoropropoxy, the perfluoroethoxy, the 1,2,2-trifluoroethoxy, in particular the 1,1,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and preferably the difluoromethoxy group.

1238EPORD01 2003-12 04

- 3 -

Fluoro-1-4C-alkoxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by a fluoro-1-4C-alkoxy group. Examples of fluoro-1-4C-alkoxy-1-4C-alkyl groups are the 1,1,2,2-tetrafluoroethoxymethyl, the 2,2,2-trifluoroethoxymethyl, the trifluoromethoxyethyl and the difluoromethoxyethyl group.

Hydroxy-1-4C-alkyl represents one of the aforementioned 1-4C-alkyl groups, which is substituted by a hydroxy group. Examples which may be mentioned are the hydroxymethyl, the 2-hydroxyethyl and the 3-hydroxypropyl group.

Possible salts of compounds of the formula 1 - depending on substitution - are especially all acid addition salts. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids customarily used in pharmacy. Those suitable are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are used in salt preparation - depending on whether a mono- or polybasic acid is concerned and on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.

Pharmacologically intolerable salts, which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, are converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.

It is known to the person skilled in the art that the compounds according to invention and their salts, if, for example, they are isolated in crystalline form, can contain various amounts of solvents. The invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula 1, and also all solvates and in particular all hydrates of the salts of the compounds of the formula 1.

Compounds to be emphasized are those of the formula 1 where

- R1 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,
 - R2 is hydrogen or 1-4C-alkyl,
 - R3 is hydrogen, 1-4C-alkyl, 3-5C-cycloalkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl and
 - R4 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl
 - R5 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
 - R6 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
- and the salts of these compounds.

Compounds to be particularly emphasized are those of the formula 1 where

- R1 is 1-4C-alkyl,

1238EPORD01 2003-12 04

- 4 -

R2 is 1-4C-alkyl,

R3 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl


R4 is hydrogen,

R5 is hydrogen,

R6 is hydrogen

and the salts of these compounds.

Among the compounds of the formula 1 according to the invention, emphasis is given to the optically pure compounds of the formula 1a



and the salts of these compounds.

Particular emphasis is given to the compounds of the formula 1a, where

R1 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen, 1-4C-alkyl, 3-5C-cycloalkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl and

R4 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl

R5 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl

R6 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl

and the salts of these compounds.

Compounds to be particularly emphasized are those of the formula 1a, where

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl,

R3 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,

R4 is hydrogen,

R5 is hydrogen,

R6 is hydrogen

and the salts of these compounds.

Particularly preferred are the compounds given as final products of formula 1 in the examples, and the salts of these compounds.


1238EPORD01 2003-12 04

- 5 -

The compounds according to the invention can be synthesized from corresponding starting compounds, for example according to the reaction schemes given below. The synthesis is carried out in a manner known to the expert, for example as described in more detail in the following examples.


The compounds of the formula 1 can be obtained for example starting from compounds of the formula 2 following the reaction sequence shown in scheme 1. Oxidation of compounds of the formula 2 to compounds of the formula 3 is performed by standard procedures, for example using manganese dioxide. Reduction of the keto group in compounds of the formula 3 to the corresponding diols of the formula 1 (R3, R4 = H) can be carried out, for example, using sodium borohydride followed, if desired, by customary derivatization reactions which are familiar to the person skilled in the art (e.g. by alkylation or by acylation) to give compounds of the formula 1 with R3 and/or R4 ≠ H.

Scheme 1:



Compounds of the formula 2 can be prepared for example as outlined in scheme 2. In a first step ketones of the formula 4 are reacted with protected phenylisoserine derivatives of the formula 5 (wherein Y is a suitable leaving group, for example an ethoxy group and Prot is a suitable protecting group like a suitable silyl radical, for example a $^t\text{BuMe}_2\text{Si-}$ radical) to give compounds of the formula 6 and/or compounds of the formula 2. Compounds of the formula 6, if obtained, can be deprotected by standard procedures to the desired compounds of the formula 2.

Scheme 2:




1238EPORD01 2003-12 04

- 6 -

The synthesis as outlined in scheme 2a leads to the preferred optically pure compound of the formula 1a by reacting ketones of the formula 4 with optically pure phenylisoserin derivatives of the formula 5a and further chemical transformations as described for scheme 1.

Scheme 2a:




Ketones of the formula 4 are known, for example from *Helvetica Chimica Acta* (1979), 62, 507, or can be prepared in a manner as shown for example in scheme 3 (route A). 3-Nitro-2-aminophenol can be reacted in a first step with a suitable benzyl derivative, for example benzylchloride, and the amino group of the reaction product of the formula 8 (known from *J. Heterocyclic Chem.* (1983), 20, 1525) is converted to the di-amide of the formula 9. Subsequent reduction under standard conditions, for example using hydrazine N_2H_4 in the presence of $FeCl_2$, leads to the formation of the primary amide of the formula 10, whose amine functionality can be alkylated in a next step, for example under reductive alkylation conditions, to compounds of the formula 11. The following cyclization step is performed under standard conditions, for example under acidic conditions using $POCl_3$, to give compounds of the formula 12 whose hydrogenation to the desired compounds of the formula 4 is performed in manner known to the expert, for example as described by H. Oelschlaeger and H. Giebenhain in *Archiv der Pharmazie*, 1973, 306, 485-489.

1238EPORD01 2003-12 04


- 7 -

Scheme 3 (route A):



Alternatively, the ketones of the formula 4 can be prepared from compounds of the formula 15 by a cyclization reaction in the presence of a primary amine as shown in scheme 4 (route B). Compounds of the formula 15 are known, for example from H. Stetter and K. Hoehne, Chem. Ber., 1958, 91, 1123-1128, or can be prepared in an analogous manner starting from 2-nitroresorcin as shown in scheme 4.

Scheme 4 (route B):




1238EPORD01 2003-12 04

- 8 -


Phenylisoserine derivatives of the formula 5 or 5a can be prepared in analogy to methods known in literature (see for example J. Amer. Chem. Soc. (1998), 120, 431) or by methods known to the expert, for example by reaction under basic conditions of the corresponding unprotected phenylisoserine derivatives of the formula 16 with suitable protection group precursor Prot-X with a suitable leaving group X, like a suitable silyl chloride, for example $t\text{BuMe}_2\text{SiCl}$, as shown in Scheme 5.

Scheme 5:



Compounds of the formula 16 are known or can be prepared by methods known to the expert, for example by epoxidation of the corresponding cinnamic acid derivatives of the formula 17, followed by a ring opening reaction or directly by a aminohydroxylation reaction. Both variants can be performed in a stereoselective way, which leads for example to compounds of the formula 16a, as shown in Scheme 6.

Scheme 6:



The invention further relates to the process and the process intermediates described in the above schemes, in particular the process described in scheme 1 and the process intermediates of the general formulae 3 and 3a as outlined in schemes 1 and 2a.

The following examples serve to illustrate the invention in greater detail without restricting it. Likewise, further compounds of the formula 1 whose preparation is not described explicitly can be prepared in an analogous manner or in a manner familiar per se to the person skilled in the art using customary process techniques. The abbreviation min stands for minute(s), h for hour(s) and m.p. for melting point.

1238EPORD01 2003-12 04

- 9 -

Examples**I. Final Products of formula 1****1. (6R,7R,8R)-2,3-Dimethyl-7-hydroxy-6-(2-methoxyethoxy)-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline**

To a at -10°C cooled stirred suspension of 2.50 g (8.08 mmol) (6R,7R,8R)-2,3-dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline in 2-methoxyethanol is added 0.99 ml (17.8 mmol) conc. sulphuric acid. The reaction mixture is stirred for further 5 h. The mixture is poured out into a saturated sodium hydrogen carbonate solution and extracted with ethyl acetate three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3 and ethyl acetate: 100) to give 0.40 g (1.09 mmol / 13 %) of the title product as a light brown foam.

¹H-NMR (200MHz, CDCl₃): δ = 2.51 (s, 3 H), 3.38 (s, 3 H), 3.54-3.63 (m, 2 H), 3.66 (s, 3 H), 3.86-4.11 (m, 2 H), 4.21 (dd, 1 H), 4.49 (d, 1 H), 4.87 (dd, 1 H), 6.67 (d, 1 H), 7.23 (1d, 1 H), 7.31-7.42 (m, 3 H), 7.52-7.56 (m, 2 H).

2. (6S,7R,8R)-2,3-Dimethyl-7-hydroxy-6-(2-methoxyethoxy)-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline

To a at -10°C cooled stirred suspension of 2.50 g (8.08 mmol) (6R,7R,8R)-2,3-dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline in 2-methoxyethanol is added 0.99 ml (17.8 mmol) conc. sulphuric acid. The reaction mixture is stirred for further 5 h. The mixture is poured out into a saturated sodium hydrogen carbonate solution and extracted with ethyl acetate three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3 and ethyl acetate: 100) to give 1.50 g (4.09 mmol / 51 %) of the title product as a light brown foam.

¹H-NMR (200MHz, CDCl₃): δ = 2.52 (s, 3 H), 3.40 (s, 3 H), 3.58-3.63 (m, 2 H), 3.66 (s, 3 H), 3.78-4.00 (m, 2 H), 4.06 (bd, 1H), 4.55-4.59 (m, 2 H), 6.61 (d, 1 H), 7.09 (1d, 1 H), 7.30-7.40 (m, 3 H), 7.50-7.54 (m, 2 H).

3. (6R,7R,8R)-2,3-Dimethyl-6-ethoxy-7-hydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline

To a at -10°C cooled stirred suspension of 2.00 g (6.50 mmol) (6R,7R,8R)-2,3-dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline in ethanol (40 ml) is added 0.79 ml (14.3 mmol) conc. sulphuric acid. The reaction is warmed up to 25°C and stirred for further 3 h. The mixture is poured out into a saturated sodium hydrogen carbonate solution and extracted with ethyl acetate three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3). The obtained solid is crystallized from ethyl acetate to give 0.09 g (0.27 mmol / 4.0 %) of the title product as a colourless solid with a melting point of 177.5°C (ethyl acetate).

1238EPORD01 2003-12 04

- 10 -

4. (6S,7R,8R)-2,3-Dimethyl-6-ethoxy-7-hydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline

To a at -10°C cooled stirred suspension of 2.00 g (6.50 mmol) (6R,7R,8R)-2,3-dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline in ethanol (40 ml) is added 0.79 ml (14.3 mmol) conc. sulphuric acid. The reaction is warmed up to 25°C and stirred for further 3 h. The mixture is poured out into a saturated sodium hydrogen carbonate solution and extracted with ethyl acetate three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3). The obtained solid is crystallized from ethyl acetate to give 1.50 g (4.44 mmol / 68 %) of the title product as a colourless solid with a melting point of 169.9°C (ethyl acetate).

5. (6R,7R,8R)-2,3-Dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline
To a stirred suspension of 2.00 g (6.50 mmol) (7R,8R)-7-hydroxy-2,3-dimethyl-8-phenyl-8,9-dihydro-3H,7H-imidazo[4,5-h]quinolin-6-one in methanol (40 ml) is added 0.50 g (13.22 mmol) sodium boron hydride and it is stirred for further 1 h. Subsequently the reaction is quenched by pouring it out into a saturated ammonium chloride solution. The mixture is extracted with dichloromethane three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3 to 13 / 1). The obtained solid is crystallized from acetone to give 2.00 g (6.50 mmol / 100 %) of the diastereomeric mixture of the expected diols. This mixture is separated by column chromatography (ethyl acetate) to give 1.75 g (5.65 mmol / 87 %) of the title product as a colourless solid with a melting point of 224.7°C (ethyl acetate).

6. (6S,7R,8R)-2,3-Dimethyl-6,7-dihydroxy-8-phenyl-6,7,8,9-tetrahydro-3H-imidazo[4,5-h]quinoline
To a stirred suspension of 2.00 g (6.50 mmol) (7R,8R)-7-hydroxy-2,3-dimethyl-8-phenyl-8,9-dihydro-3H,7H-imidazo[4,5-h]quinolin-6-one in methanol (40 ml) is added 0.50 g (13.22 mmol) sodium boron hydride and it is stirred for further 1 h. Subsequently the reaction is quenched by pouring it out into a saturated ammonium chloride solution. The mixture is extracted with dichloromethane three times. The combined organic layers are concentrated in vacuo and purified by column chromatography (dichloromethane / methanol: 100 / 3 to 13 / 1). The obtained solid is crystallized from acetone to give 2.00 g (6.50 mmol / 100 %) of the diastereomeric mixture of the expected diols. This mixture is separated by column chromatography (ethyl acetate) to give 0.15 g (0.48 mmol / 7.5 %) of the title product as a colourless solid with a melting point of 235.4°C (ethyl acetate).

1238EPORD01 2003-12 04

- 11 -

II. Starting compounds and Intermediates:**A. 2-Benzoyloxy-6-nitroaniline**

To a solution of 50.0 g (0.31 mol) 2-amino-3-nitrophenol in ethanol (400 ml) is added 43.5 ml (0.38 mol) benzyl chloride, 47.8 g (0.35 mol) potassium carbonate and 2.00 g (13.3 mmol) sodium iodide and it is stirred at 80°C for 3.5 h. Subsequently the mixture is concentrated in vacuo, redissolved in dichloromethane, washed with water, dried over sodium sulfate, filtrated over sand and concentrated in vacuo again. The crude product is purified by column chromatography (cyclohexane / ethyl acetate: 8 / 2) to give 76.0 g (0.31 mol / 96 %) of the title product.

¹H-NMR (200MHz, CDCl₃): δ = 5.11 (s, 2 H), 6.57 (t, 1 H), 6.95 (d, 1 H), 7.35-7.44 (m, 5 H), 7.73 (d, 1 H).

B. N-Acetyl-2-benzoyloxy-6-nitro-acetanilide

To a stirred reaction mixture of 76.0 g (0.31 mol) 2-benzoyloxy-6-nitroaniline in acetic anhydride (469 ml) is added 7.60 ml (0.12 mol) methane sulfonic acid and is stirred for 2 h at 120°C. Afterwards the acetic anhydride is removed in vacuo and the residue is poured into ice water. This mixture is neutralised with concentrated ammonia solution and extracted with dichloromethane three times. The combined organic layers are concentrated and dried in vacuo to give 99.9 g (0.30 mol / 98 %) of the title product with a melting point of 113.8°C (dichloromethane).

C. 2-Amino-6-benzoyloxy-acetanilide

To a stirred mixture of 99.6 g (0.30 mol) N-acetyl-2-benzoyloxy-6-nitro-acetanilide, activated carbon (59.7 g) and 30.0 g (18.5 mmol) iron (III) chloride in methanol (2.60 l) at 70°C is added dropwise 147 ml (3.03 mol) hydrazine hydrate and is stirred for further 5 h. Subsequently the mixture is filtrated over kieselgur and concentrated in vacuo. The crude mixture is suspended in a saturated ammonium chloride solution and extracted with dichloromethane twice. The combined organic layers are concentrated in vacuo and the crude product is reslurried in diethyl ether to give 50.5 g (0.20 mol / 65 %) of the title product with a melting point of 146.9°C (diethyl ether).

D. 4-Benzoyloxy-1,2-dimethyl-1H-benzimidazole

To a stirred mixture of 4.00 g (17.0 mmol) 2-amino-6-benzoyloxy-acetanilide in dichloromethane (8.0 ml) is added 4.00 ml (4.30 mmol) phosoryl chloride and is stirred at 70°C for 5 h. Subsequently the mixture is poured into ice water, neutralised by adding sodium hydroxide solution (6 N) and extracted with dichloromethane three times. The combined organic layers are concentrated in vacuo and the crude product is purified by column chromatography (diethyl ether / petrol ether: 7 / 3) to give 3.09 g (12.2 mmol / 72 %) of the title product with a melting point of 130.9°C (diethyl ether / petrol ether).

E. 1,2-Dimethyl-1,5,6,7-tetrahydro-benzimidazol-4-one

Route A: A suspension of 2.00 g (7.93 mmol) 4-benzoyloxy-1,2-dimethyl-1H-benzimidazole and 1.70 g palladium on carbon (10 %) in methanol (50 ml) is stirred in a autoclave at a hydrogen pressure of 150 bar at 70°C for 20 h. Afterwards the catalyst is filtered off and the methanol is removed in vacuo. The crude product

1238EPORD01 2003-12 04

- 12 -

is purified by column chromatography (dichloromethane / methanol: 100 / 3 to 13 / 1) to give 0.14 g (0.85 mmol / 11 %) of the title product with a melting point of 98.1°C (dichloromethane / methanol).

Route B: To a stirred mixture of 29.0 g (0.17 mol) 2-acetylamino-3-hydroxy-cyclohex-2-enone in xylene (580 ml) is added acetic acid (57 ml) and dropwise 116 ml (0.23 mol) methylamine (2 M in THF). The reaction mixture is heated to 155°C for 5 h, cooled down to 25°C and stirred for further 20 h. Afterwards the mixture is concentrated in vacuo and the crude product is purified by column chromatography (ethyl acetate / methanol: 8 / 2) to yield 21.4 g (0.13 mol / 77 %) of the title product with a melting point of 98.1°C (ethyl acetate / methanol).

F. (2R,3R)-3-amino-2-(tert-butyl-dimethyl-silanyloxy)-3-phenyl propionic acid ethyl ester
1323 g (4.06 mole) of (R, R)-phenylisoserine ethyl ester are dissolved in 6.6. L of dichloromethane. To this solution, 397.4 g of imidazole and 724 g of t-butyldimethylsilyl chloride are added. The mixture is stirred for 16 hrs at RT. The reaction mixture is washed subsequently with 6 L and 4 L of water. The resulting clear dichloromethane layer is dried over sodium sulphate, filtered and concentrated under reduced pressure. The obtained 1509 g of the title compound is used as such without further purification.

G. (7R,8R)-7-Hydroxy-2,3-dimethyl-8-phenyl-5,7,8,9-tetrahydro-3H,4H-imidazo[4,5-h]quinolin-6-one
A mixture of 6.20 g (37.8 mmol) 1,2-dimethyl-1,5,6,7-tetrahydro-benzimidazol-4-one and 12.5 g (38.6 mmol) (2R,3R)-3-amino-2-(tert-butyl-dimethyl-silanyloxy)-3-phenyl propionic acid ethyl ester is heated to 170°C and is stirred for 5.5 h. Afterwards the solid is purified by column chromatography (dichloromethane / methanol: 100 / 1 to 13 / 1) to give 6.35 g (20.5 mmol / 54 %) of the title product as a light brown solid with a melting point of 262.3°C (dichloromethane / methanol).

H. (7R,8R)-7-(tert-Butyl-dimethyl-silanyl-oxy)-2,3-dimethyl-8-phenyl-5,7,8,9-tetrahydro-3H,4H-imidazo[4,5-h]quinolin-6-one

A mixture of 6.20 g (37.8 mmol) 1,2-dimethyl-1,5,6,7-tetrahydro-benzimidazol-4-one and 12.5 g (38.6 mmol) (2R,3R)-3-amino-2-(tert-butyl-dimethyl-silanyloxy)-3-phenyl propionic acid ethyl ester is heated to 170°C and is stirred for 5.5 h. Afterwards the solid is purified by column chromatography (dichloromethane / methanol: 100 / 1 to 13 / 1) to give 2.20 g (5.19 mmol / 14 %) of the title product. This compound is transformed by acetic standard condition without any characterisation into (7R,8R)-7-hydroxy-2,3-dimethyl-8-phenyl-5,7,8,9-tetrahydro-3H,4H-imidazo [4,5-h]quinolin-6-one.

I. (7R,8R)-7-Hydroxy-2,3-dimethyl-8-phenyl-5,8,9-dihydro-3H,7H-imidazo[4,5-h]quinolin-6-one

A reaction mixture of 6.20 g (20.0 mmol) (7R,8R)-7-hydroxy-2,3-dimethyl-8-phenyl-5,7,8,9-tetrahydro-3H,4H-imidazo[4,5-h]quinolin-6-one and 19.0 g (197 mmol) manganese dioxide in dichloromethane (250 ml) is stirred for 20 h at 25°C. Afterwards the manganese residues are filtered off by using kieselgur. The crude product is purified by column chromatography (dichloromethane / methanol: 100 / 1 to 13 / 1) and crystallized from acetone to give 4.70 g (15.3 mmol / 76 %) of the title product as a solid with a melting point of 235.1°C (acetone).

1238EPORD01 2003-12 04

- 13 -

Commercial Utility

The compounds of the formula 1 and their salts have valuable pharmacological properties which make them commercially utilizable. In particular, they exhibit marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective action in warm-blooded animals, in particular humans. In this connection, the compounds according to the invention are distinguished by a high selectivity of action, an advantageous duration of action, a particularly good enteral activity, the absence of significant side effects and a large therapeutic range.

"Gastric and intestinal protection" in this connection is understood as meaning the prevention and treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions (such as, for example, gastric ulcer, peptic ulcer, including peptic ulcer bleeding, duodenal ulcer, gastritis, hyperacidic or medicament-related functional dyspepsia), which can be caused, for example, by microorganisms (e.g. *Helicobacter pylori*), bacterial toxins, medicaments (e.g. certain antiinflammatories and antirheumatics, such as NSAIDs and COX-inhibitors), chemicals (e.g. ethanol), gastric acid or stress situations. "Gastric and intestinal protection" is understood to include, according to general knowledge, gastroesophageal reflux disease (GERD), the symptoms of which include, but are not limited to, heartburn and/or acid regurgitation.

In their excellent properties, the compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in various models in which the antilulcerogenic and the antisecretory properties are determined. On account of these properties, the compounds of the formula 1 and their pharmacologically acceptable salts are outstandingly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine.

A further subject of the invention are therefore the compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.

The invention likewise includes the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the abovementioned diseases.

The invention furthermore includes the use of the compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.

A further subject of the invention are medicaments which comprise one or more compounds of the formula 1 and/or their pharmacologically acceptable salts.

1238EPORD01 2003-12 04

- 14 -

The medicaments are prepared by processes which are known per se and familiar to the person skilled in the art. As medicaments, the pharmacologically active compounds according to the invention (= active compounds) are either employed as such, or preferably in combination with suitable pharmaceutical auxiliaries or excipients in the form of tablets, coated tablets, capsules, suppositories, patches (e.g. as TTS), emulsions, suspensions or solutions, the active compound content advantageously being between 0.1 and 95% and it being possible to obtain a pharmaceutical administration form exactly adapted to the active compound and/or to the desired onset and/or duration of action (e.g. a sustained-release form or an enteric form) by means of the appropriate selection of the auxiliaries and excipients.

The auxiliaries and excipients which are suitable for the desired pharmaceutical formulations are known to the person skilled in the art on the basis of his/her expert knowledge. In addition to solvents, gel-forming agents, suppository bases, tablet auxiliaries and other active compound excipients, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins).

The active compounds can be administered orally, parenterally or percutaneously.

In general, it has proven advantageous in human medicine to administer the active compound(s) in the case of oral administration in a daily dose of approximately 0.01 to approximately 20, preferably 0.05 to 5, in particular 0.1 to 1.5, mg/kg of body weight, if appropriate in the form of several, preferably 1 to 4, individual doses to achieve the desired result. In the case of a parenteral treatment, similar or (in particular in the case of the intravenous administration of the active compounds), as a rule, lower doses can be used. The establishment of the optimal dose and manner of administration of the active compounds necessary in each case can easily be carried out by any person skilled in the art on the basis of his/her expert knowledge.

If the compounds according to the invention and/or their salts are to be used for the treatment of the abovementioned diseases, the pharmaceutical preparations can also contain one or more pharmacologically active constituents of other groups of medicaments, for example: tranquilizers (for example from the group of the benzodiazepines, for example diazepam), spasmolytics (for example, biefamiverine or camylofine), anticholinergics (for example, oxyphencyclimine or phencarbamide), local anesthetics, (for example, tetracaine or procaine), and, if appropriate, also enzymes, vitamins or amino acids.

To be emphasized in this connection is in particular the combination of the compounds according to the invention with pharmaceuticals which inhibit acid secretion, such as, for example, H_2 blockers (e.g. cimetidine, ranitidine), H^+/K^+ ATPase inhibitors (e.g. omeprazole, pantoprazole), or further with so-called peripheral anticholinergics (e.g. pirenzepine, telenzepine) and with gastrin antagonists with the aim of increasing the principal action in an additive or super-additive sense and/or of eliminating or of decreasing the side effects, or further the combination with antibacterially active substances (such as, for example, cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or alternatively bismuth salts) for the control of *Helicobacter pylori*. Suitable antibacterial co-components which may be mentioned are, for

1238EPORD01 2003-12 04

- 15 -

example, mezlocillin, ampicillin, amoxicillin, cefalothin, cefoxitin, cefotaxime, imipenem, gentamycin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (for example clarithromycin + metronidazole).

In view of their excellent gastric and intestinal protection action, the compounds of formula 1 are suited for a free or fixed combination with those medicaments (e.g. certain antiinflammatories and antirheumatics, such as NSAIDs), which are known to have a certain ulcerogenic potency. In addition, the compounds of formula 1 are suited for a free or fixed combination with motility-modifying drugs.

1238EPORD01 2003-12 04

- 16 -

Pharmacology

The excellent gastric protective action and the gastric acid secretion-inhibiting action of the compounds according to the invention can be demonstrated in investigations on animal experimental models. The compounds according to the invention investigated in the model mentioned below have been provided with numbers which correspond to the numbers of these compounds in the examples.

Testing of the secretion-inhibiting action on the perfused rat stomach

In Table A which follows, the influence of the compounds of the formula 1 according to the invention on the pentagastrin-stimulated acid secretion of the perfused rat stomach after intraduodenal administration in vivo is shown.

Table A

No.	Dose (μ mol/kg) i.d.	Inhibition of acid secretion (%)
1	2.0	> 50
2	2.0	< 50
3	2.0	> 50
4	2.0	< 50
5	2.0	> 50
6	2.0	< 50

Methodology

The abdomen of anesthetized rats (CD rat, female, 200-250 g; 1.5 g/kg i.m. urethane) was opened after tracheotomy by a median upper abdominal incision and a PVC catheter was fixed transorally in the esophagus and another via the pylorus such that the ends of the tubes just projected into the gastric lumen. The catheter leading from the pylorus led outward into the right abdominal wall through a side opening.

After thorough rinsing (about 50-100 ml), warm (37°C) physiological NaCl solution was continuously passed through the stomach (0.5 ml/min, pH 6.8-6.9; Braun-Unita I). The pH (pH meter 632, glass electrode EA 147; ϕ = 5 mm, Metrohm) and, by titration with a freshly prepared 0.01N NaOH solution to pH 7 (Dosimat 665 Metrohm), the secreted HCl were determined in the effluent in each case collected at an interval of 15 minutes.

The gastric secretion was stimulated by continuous infusion of 1 μ g/kg (= 1.65 ml/h) of i.v. pentagastrin (left femoral vein) about 30 min after the end of the operation (i.e. after determination of 2 preliminary fractions).

1238EPORD01 2003-12 04

- 17 -


The substances to be tested were administered intraduodenally in a 2.5 ml/kg liquid volume 60 min after the start of the continuous pentagastrin infusion. The body temperature of the animals was kept at a constant 37.8-38°C by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).

1238EPORD01 2003-12 04

- 18 -

Patent Claims

1. A compound of the formula 1



in which

- R1 is hydrogen, halogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkoxycarbonyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R2 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, fluoro-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R3 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl,
- R4 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl
- R5 is hydrogen, halogen, 1-4C-alkyl or fluoro-1-4C-alkyl
- R6 is hydrogen, halogen, 1-4C-alkyl or fluoro-1-4C-alkyl
- and its salts.

2. A compound of the formula 1 as claimed in claim 1, in which

- R1 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,
- R2 is hydrogen or 1-4C-alkyl,
- R3 is hydrogen, 1-4C-alkyl, 3-5C-cycloalkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl and
- R4 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl
- R5 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
- R6 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
- and its salts.

3. A compound of the formula 1 as claimed in claim 1, in which


- R1 is 1-4C-alkyl,

1238EPORD01 2003-12 04

- 19 -

- R2 is 1-4C-alkyl,
R3 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl
R4 is hydrogen,
R5 is hydrogen,
R6 is hydrogen
and its salts.

4. A compound of the formula 1 as claimed in claim 1, characterized by the formula 1a,



In which

- R1 is hydrogen, 1-4C-alkyl or 3-7C-cycloalkyl,
R2 is hydrogen or 1-4C-alkyl,
R3 is hydrogen, 1-4C-alkyl, 3-5C-cycloalkyl, 1-4C-alkoxy-1-4C-alkyl, fluoro-1-4C-alkyl, fluoro-1-4C-alkoxy-1-4C-alkyl or hydroxy-1-4C-alkyl and
R4 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl
R5 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
R6 is hydrogen, fluoro, 1-4C-alkyl or fluoro-1-4C-alkyl
and its salts.


5. A compound of the formula 1a as claimed in claim 4,
in which

- R1 is 1-4C-alkyl,
R2 is 1-4C-alkyl,
R3 is hydrogen, 1-4C-alkyl or 1-4C-alkoxy-1-4C-alkyl,
R4 is hydrogen,
R5 is hydrogen,
R6 is hydrogen
and its salts.

1238EPORD01 2003-12 04

- 20 -

6. A compound of the formula 3



in which

R1, R2, R5 and R6 have the meanings as indicated in claim 1 and its salts.

7. A process for the synthesis of compounds of the formula 1 as claimed in claim 1, which comprises
- converting compounds of the formula 3 as claimed in claim 6 to compounds of the formula 1 as claimed in claim 1 with R3 and R4 = H
 - if desired, further derivatization of the reaction product of the formula 1 with R3, R4 = H to compounds of the formula 1 with R3 and / or R4 ≠ H.
8. A medicament comprising a compound as claimed in claim 1 and/or a pharmacologically acceptable salt thereof together with customary pharmaceutical auxiliaries and/or excipients.
9. The use of a compound as claimed in claim 1 and its pharmacologically acceptable salts for the prevention and treatment of gastrointestinal disorders.

1238EPORD01 2003-12 04

- 21. -

Abstract

The invention relates to 6,7,8,9-Tetrahydro-3H-imidazo[4,5-h]quinolines of formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP04/053544

International filing date: 16 December 2004 (16.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 03028846.8
Filing date: 16 December 2003 (16.12.2003)

Date of receipt at the International Bureau: 22 February 2005 (22.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **CRACKS OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.